Moreover, Navarro et al. reported that the detection of GAL-1 circulating levels shows strong potential for use as a novel biomarker for the diagnosis of pancreatic ductal adenocarcinoma (PDA) patients [53]. Here, LGALS1 is linked to pancreatic ductal adenocarcinoma.